Cost-Effectiveness Analysis of Eltrombopag As Support Treatment In Chronic Hcv Infected Patients With Thrombocytopenia To Enable Interferon-Based Regimens.

• A two-phase individual-level model was developed to evaluate the costeffectiveness of eltrombopag treatment in thrombocytopenic HCVpatients over a lifetime horizon. • Individual-level models are more flexible and provide more accurate estimations than Markov approaches. • A set of mathematical distributions were developed using data from trials ENABLE 1 and 22 and local studies3,4, to describe patient characteristics. • From these distributions, one million theoretical patients were generated and the evolution of each one of them through the patient flow (Figure 1) was simulated for the two treatment alternatives (with and without eltrombopag).